ClinicalTrials.gg
RecruitingNCT06267183Updated Aug 14, 2026

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

An Early Phase 1 interventional study of SV001 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Shanghai Synvida Biotechnology Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Shanghai Synvida Biotechnology Co.,Ltd. · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
38th of 60
53 · median 83
Started
2024
with 7 others
Phase 1
20 of 67
5 open now
Primary completion
2026-11
later than 6 of 28 live
Registered
38th of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 38th largest by planned enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2024, is one of 20 in phase 1, reaches primary completion later than 6 of the 28 other live ones, and was the 38th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must fully understand the purpose, characteristics, methods and possible adverse reactions of the trial, volunteer as a subject, and sign the Form;
  2. Subjects must have a in the range of 19\~26 kg/m2, with males weighted not less than 50 kg, and females weighted not less than 45 kg;
  3. Subjects must be in good health as judged by the investigator.
  4. Reliable must be assured during and for some time after the trial.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of drug or other substance anaphylaxis;
  2. Subjects with respiratory symptoms or abnormal respiratory tract;
  3. Subjects currently having an oral disease that the investigator judged may affect use of the trial drug and devices;
  4. Subjects with other diseases or factors with abnormal clinical manifestations;
  5. Subjects having a history of drug abuse in the past or having used narcotics in the period prior to screening, or having a positive result in urine narcotics test at baseline period;
  6. Subjects who smoked more than 5 cigarettes a day in the period before screening;
  7. Subjects who consumed more than 14 units of alcohol per week in the period prior to screening, or who is positive in breath alcohol test at baseline period;
  8. Subjects who have suffered a severe disease or undergone major surgical operations within a certain period of time prior to receiving the drug, or who are expected to require major operations during the clinical trial;
  9. Subjects who used other drugs within a certain period of time before receiving the investigational drug;
  10. Screening period: ≤80% predicted value or FVC≤80% predicted value;
  11. Subjects who have antibody positive for , surface antigen, or Treponema Pallidum.
  12. Subjects who have difficulty in venous blood collection or have a history of acupuncture syncope and blood phobia;
  13. Female subjects who are tested positive for pregnancy during the screening or baseline period or are in lactation period;
  14. Subjects who have participated in other drug clinical trials and used other drugs in clinical trials within a certain period of time before receiving the investigational drug;
  15. Subjects who have a history of blood donation or blood loss of more than 400 mL in the period prior to screening;
  16. Any other status in which the investigator deems inappropriate to participate in the present study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    SV001

    Drug: SV001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSV001

    SV001 : single-dose

  • DrugPlacebo

    Placebo : single-dose

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Adverse event type, incidence, duration

    Time frame: Approximately 1 years

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  2. Peak time(Tmax)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  3. Area under the plasma concentration versus time curve (AUC)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  4. half-life(T1/2)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  5. Immunogenicity

    ADA(Anti-drug antibody)

    Time frame: Approximately 1 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2026, 34 months after the start.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 34 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 20, 2024
StartActual
Jan 12, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06267183
Lead sponsor
Shanghai Synvida Biotechnology Co.,Ltd.
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Jan 12, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion